Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab

Table 1

Characteristics of the patient cohort at baseline.

Study eye, n	44
Mean age, mean ± SD, range, years	78.5 ± 9.5 (54–98)
Gender distribution, male/female	14/30 (31.8/68.2%)
Mean follow-up before switch ± SD, months	43 ± 3.6
Mean number of ranibizumab injections in the 12 months before enrollment, mean ± SD	12 ± 1
BCVA, ETDRS letters, mean ± SD (range)	64.5 ± 13 (35–80)
Central retinal thickness, μm, mean ± SD, (range)	313 ± 85 (185–508)
PED height, μm, mean ± SD, range	221 ± 120 (38–518)
Intraretinal fluid, n (%)	22 (50%)
Subretinal Fluid, n (%)	26 (59%)
Intra- and subretinal fluid	15 (34%)
Hyperreflective subretinal exudation	18 (40.9%)
IS/OS segment disruption	19 (43.2%)

BCVA: best-corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Scale; PED: pigment epithelial detachment.